Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faropenem in Bangladeshi Adult Patients With Community-Acquired Bacterial Pneumonia (CABP)
NCT06804096Phase 4Completed
- Start
- Feb 2025
- Primary completion
- Jan 2026
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 4 trial of faropenem in community-acquired bacterial pneumonia (CAP). Started Feb 2025; status: completed.
02
Drugs
faropenem
03
Conditions
community-acquired bacterial pneumonia (CAP)
Beyond the preview
Go deeper on NCT06804096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06804096.